SCHEMBL8942527

SCHEMBL8942527

CCCNC(=O)CCCC(C)C

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.54
LMNA P02545 1/20 0.49
PKM P14618 1/20 0.49
ALDH1A1 P00352 1/20 0.48
FAAH O00519 6/20 0.47
CASP2 P42575 1/20 0.47
HPGD P15428 1/20 0.46
DNM1 Q05193 2/20 0.44
NAAA Q02083 1/20 0.44
PLA2G10 O15496 2/20 0.44
MCL1 Q07820 1/20 0.42
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10888613 0.92 FAAH (0.53) CNR1LMNAPKMALDH1A1FAAH
SCHEMBL19194057 0.92 FAAH (0.53) CNR1LMNAPKMALDH1A1FAAH
SCHEMBL13328249 0.88 LMNA (0.60) CNR1LMNAPKMALDH1A1FAAH
SCHEMBL1518045 0.88 ALDH1A1 (0.57) CNR1LMNAPKMALDH1A1FAAH
SCHEMBL20206555 0.86 CNR1 (0.56) CNR1LMNAPKMALDH1A1FAAH
SCHEMBL23472179 0.85 FAAH (0.61) CNR1FAAHCASP2DNM1NAAA
SCHEMBL27998259 0.85 FAAH (0.56) CNR1LMNAPKMFAAHCASP2
SCHEMBL19249120 0.85 CASP2 (0.58) CNR1LMNAPKMALDH1A1FAAH
SCHEMBL24826063 0.84 CNR1 (0.52) CNR1LMNAPKMALDH1A1FAAH
SCHEMBL4904632 0.84 CASP2 (0.62) CNR1LMNAPKMALDH1A1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968212-B2 Compounds having estrogen receptor alpha degradation activity and uses thereof ACCUTAR BIOTECHNOLOGY INC. (US) 2021-04-06 US disclosed
US-9981954-B2 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-05-29 US disclosed
US-20180002314-A1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-01-04 US disclosed
WO-2017176040-A1 HETEROCYCLIC COMPOUND DECOMPOSING RAS AND USES THEREOF 연세대학교 산학협력단 2017-10-12 WO disclosed
US-9290584-B2 Polyalkylene carboxylic acid polyamine additives for fouling mitigation in hydrocarbon refining processes EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-03-22 US disclosed
US-20130008830-A1 POLYALKYLENE CARBOXYLIC ACID POLYAMINE ADDITIVES FOR FOULING MITIGATION IN HYDROCARBON REFINING PROCESSES EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2013-01-10 US disclosed
EP-0699187-A1 DERIVATIVES OF -g(b), -g(b)-DIMETHYL-4-PIPERIDINEETHANAMINE AS INHIBITORS OF THE CHOLESTEROL BIOSYNTHESIS FOURNIER IND & SANTE (FR) 1996-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130008830-A1 POLYALKYLENE CARBOXYLIC ACID POLYAMINE ADDITIVES FOR FOULING MITIGATION IN HYDROCARBON REFINING PROCESSES PFAS, PCBP1, PARG CNR1 3052/4885LMNA 1050/4885PKM 355/4885
US-20180002314-A1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS SCNN1A, TRPV1, SCNN1B CNR1 3767/4885LMNA 560/4885PKM 356/4885
US-10968212-B2 Compounds having estrogen receptor alpha degradation activity and uses thereof ESR2, ESRRG, ESR1 CNR1 487/4885LMNA 1648/4885PKM 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.